Prasinezumab: Advancing Towards the First Disease Modifying Treatment for Parkinson’s Disease

• Demonstrating clinical potential of Prasinezumab to delay motor progression, highlighting meaningful functional benefit for patients
• Outlining α-synuclein targeting mechanism with supporting biomarker evidence to validate biological activity and translational relevance
• Exploring future Phase III directions and beyond to position Prasinezumab as a first-in-class disease-modifying therapy

VIRTUAL

Speakers:

Gennaro Pagano

Group Leader & Expert Director - Early Development Medical Fellowship in Neuroscience & Rare Disease

Roche